

William P. Deni, Jr.  
Charles H. Chevalier  
J. Brugh Lower  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545

*Attorneys for Plaintiffs*

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

BAUSCH HEALTH IRELAND LIMITED  
and ASSERTIO THERAPEUTICS INC.,

Plaintiffs,

v.

EMCURE PHARMACEUTICALS LTD.,

Defendant.

Civil Action No. 19-14480

*Document Electronically Filed*

**COMPLAINT**

This is a patent infringement action brought by Plaintiffs Bausch Health Ireland Limited (“Bausch Ireland”) and Assertio Therapeutics Inc. (“Assertio”) (collectively, “Plaintiffs”) for infringement of U.S. Patent Nos. 6,723,340 (the “340 Patent”), 7,780,987 (the “987 Patent”) and 8,323,692 (the “692 Patent”) (collectively “Patents-in-Suit”) by Defendant Emcure Pharmaceuticals Ltd. (“Emcure” or “Defendant”), through the filing of Abbreviated New Drug Application (“ANDA”) No. 213241 for the approval of Defendant’s generic version of Plaintiffs’ Glumetza® products described therein. Plaintiffs hereby allege as follows:

### **THE PARTIES**

1. Plaintiff Bausch Ireland is a private company incorporated in Ireland with its office located at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland.

2. Plaintiff Assertio is a corporation organized and existing under the laws of Delaware, having a principal place of business at 100 S. Saunders Road, Suite 300, Lake Forest, Illinois 60045.

3. On information and belief, Defendant Emcure is a company organized and existing under the laws of India, with a principal place of business at Emcure House, T 184, M.I.D.C., Bhosari, Pune, Maharashtra 411026, India.

4. On information and belief, Emcure together with its subsidiaries develops, manufactures, and markets pharmaceutical products in India, the United States, Canada, Europe, and internationally.

### **NATURE OF THE ACTION**

5. This is a civil action for infringement of the Patents-in-Suit. This action arises under the Patent Laws of the United States, 35 U.S.C. § 100 et seq.

6. This is an action for patent infringement arising under the patent laws of the United States (Title 35 of the United States Code) and arising from Emcure filing an ANDA with the United States Food and Drug Administration (“FDA”) seeking approval to market generic version of Plaintiffs’ Glumetza® prior to the expiration of the ’340, ’987 and ’692 Patents.

7. This action arises out of Emcure filing ANDA No. 213241 (“Emcure ANDA”) including its “Paragraph IV” certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) alleging, *inter alia*, that the Patents-in-Suit are invalid, unenforceable, and or will not be infringed by the commercial manufacture, use, sale, or importation of the Emcure ANDA Products.

**JURISDICTION AND VENUE**

8. The Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

9. This Court has personal jurisdiction over Emcure because, *inter alia*, the fact that it has committed, or aided, abetted, contributed to, and/or participated in the commission of, the tortious act of patent infringement that has led to foreseeable harm and injury to Plaintiff in this District.

10. This Court has personal jurisdiction over Emcure for the further reasons that, *inter alia*, Emcure (1) has substantial, continuous, and systematic contacts with this State, (2) markets, sells, and/or distributes generic pharmaceutical drug products to residents of this State, (3) intentionally markets and sells generic pharmaceutical drug products to residents of this State, (4) maintains a broad distributorship network within this State, and (5) enjoys substantial income from sales of its generic pharmaceutical products in this State.

11. On information and belief, Heritage Pharmaceuticals Inc. is a corporation organized under the laws of Delaware with its principal place of business at One Tower Center Blvd., Suite 1700, East Brunswick, New Jersey. Heritage Pharmaceuticals Inc. is a subsidiary and an authorized U.S. agent of Emcure.

12. Upon information and belief, Heritage Pharmaceuticals Inc. is registered with the State of New Jersey as a drug wholesaler, under Registration No. 5003360.

13. Emcure through its subsidiaries and various agents (for example Heritage Pharmaceuticals), offers generic pharmaceutical products for sale in New Jersey and elsewhere in the United States and earns revenue from the distribution and sale in New Jersey of its generic pharmaceutical products.

14. Upon information and belief, this Court has personal jurisdiction over Emcure because, on information and belief, Emcure will collaborate with Heritage Pharmaceuticals Inc. for the purposes of marketing and selling the Emcure ANDA Products once approved by the FDA.

15. Upon information and belief, Emcure has purposefully directed activities at the State of New Jersey and this litigation relates to or arises out of those activities. Emcure directly or through its affiliates and agents, such as Heritage Pharmaceuticals Inc., develops, formulates, synthesizes, manufactures, markets, imports, offers to sell, and/or sells pharmaceutical drug products including the Emcure ANDA Products in New Jersey.

16. In the alternative, Plaintiffs are further informed and believe, and on that basis allege, that this Court has personal jurisdiction over Emcure pursuant to Federal Rule of Civil Procedure 4(k)(2) because Emcure has extensive contacts with the United States, including but not limited to the above-described contact, is not subject to jurisdiction in any particular state, and exercising jurisdiction over Emcure is consistent with the laws of the United States and the United States Constitution.

17. Venue is proper as to Emcure because it is a foreign defendant and can be sued in any district.

#### **THE PATENTS-IN-SUIT**

18. On April 20, 2004, the '340 Patent entitled "Optimal Polymer Mixtures for Gastric Retentive Tablets" was duly and legally issued. The named inventors of the '340 Patent are Gloria Gusler, Bret Berner, Mei Chau, and Aimee Padua. According to the Orange Book, the expiration date of the '340 Patent is October 25, 2021. (A copy of the '340 Patent is attached as Exhibit 1.)

19. Assertio is the assignee of the '340 Patent.

20. On August 4, 2010, the '987 Patent entitled "Controlled Release Dosage Forms" was duly and legally issued. The named inventors of the '987 Patent are Fang Zhou and Paul Maes. According to the Orange Book, the '987 Patent expires on March 23, 2025. (A copy of the '987 Patent is attached as Exhibit 2.)

21. On December 4, 2012, the '692 Patent entitled "Controlled Release Dosage Forms" was duly and legally issued. The inventor of the '692 Patent is Steven Frisbee. According to the Orange Book, the '692 Patent expires on March 30, 2023. (A copy of the '692 Patent is attached as Exhibit 3.)

22. Bausch Ireland is the assignee of the '987 Patent and the '692 Patent.

**ACTS GIVING RISE TO THIS ACTION**

23. Santarus Inc. holds the approved New Drug Application No. 21748 for Glumetza® 500 mg and 1 gm dosage strengths.

24. Pursuant to 21 U.S.C. § 355(b)(1), the '340 Patent is listed in Orange Book for Glumetza® 500 mg and the '987 Patent and the '692 Patent are listed in the Orange Book for Glumetza® 1 gm.

25. On information and belief, Emcure submitted the Emcure ANDA to the FDA seeking approval to engage in the commercial manufacture, use or sale of the Emcure 500 mg product and Emcure 1000 mg product, herein collectively referred to as the "Emcure ANDA Products."

26. Plaintiff received from Emcure a letter, dated May 16, 2019, (the "Emcure Notice Letter"), stating that Emcure had certified in the Emcure ANDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), that the '340, '987 and '692 Patents are invalid, or will not be infringed

by the commercial manufacture, use, or sale of the Emcure ANDA Products (the “Paragraph IV Certification”).

27. The Emcure ANDA refers to and relies upon the Glumetza® NDA and contains data that, according to Emcure, demonstrate the bioequivalence of the Emcure ANDA Products and Glumetza®.

28. This action was commenced by Plaintiff within 45 days of the date of receipt of the Emcure Notice Letter.

**CLAIMS FOR RELIEF**

**COUNT I**  
**(Infringement of the '340 Patent)**

29. Plaintiffs reallege and incorporate by reference the allegations contained in the preceding paragraphs.

30. On information and belief, Emcure has infringed at least one claim of the '340 Patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting the Emcure ANDA, by which Emcure seeks approval from the FDA to engage in the commercial manufacture, use, offer to sell, sale within the United States, or importation into the United States of the Emcure ANDA Products prior to the expiration of the '340 Patent.

31. Moreover, if Emcure manufactures, uses, sells, offers for sale, or imports into the United States, the Emcure ANDA Products, or induces or contributes to any such conduct, prior to the expiration of the '340 Patent, including any applicable exclusivities or extensions, Emcure would further infringe (either literally or under the doctrine of equivalents) at least one claim of the '340 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

32. Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4), including an order of this Court that the effective date of the approval of the Emcure ANDA be a date that is

not earlier than the expiration of the term of the '340 Patent, including any extension(s) granted by the United States Patent and Trademark Office ("PTO") pursuant to 35 U.S.C. §§ 154 or 156, or any late expiration of exclusivity for the '340 Patent to which Plaintiffs are or become entitled.

33. Plaintiffs will be substantially and irreparably harmed if Emcure is not enjoined from infringing the '340 Patent.

34. Plaintiffs have no adequate remedy at law.

35. This case is exceptional, and Plaintiffs are entitled to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT II**  
**(Infringement the '987 Patent)**

36. Plaintiffs reallege and incorporate by reference the allegations contained in the preceding paragraphs.

37. On information and belief, Emcure has infringed at least one claim of the '987 Patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting the Emcure ANDA, by which Emcure seeks approval from the FDA to engage in the commercial manufacture, use, offer to sell, sale within the United States, or importation into the United States of the Emcure ANDA Products prior to the expiration of the '987 Patent.

38. Moreover, if Emcure manufactures, uses, sells, offers for sale, or imports into the United States, the Emcure ANDA Products, or induces or contributes to any such conduct, prior to the expiration of the '987 Patent, including any applicable exclusivities or extensions, Emcure would further infringe (either literally or under the doctrine of equivalents) at least one claim of the '987 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

39. Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4), including an order of this Court that the effective date of the approval of the Emcure ANDA be a date that is

not earlier than the expiration of the term of the '987 Patent, including any extension(s) granted by the PTO pursuant to 35 U.S.C. §§ 154 or 156, or any late expiration of exclusivity for the '987 Patent to which Plaintiffs are or become entitled.

40. Plaintiffs will be substantially and irreparably harmed if Emcure is not enjoined from infringing the '987 Patent.

41. Plaintiffs have no adequate remedy at law.

42. This case is exceptional, and Plaintiffs are entitled to an award of attorneys' fees under 35 U.S.C. § 285.

**COUNT III**  
**(Infringement of the '692 Patent)**

43. Plaintiffs reallege and incorporate by reference the allegations contained in the preceding paragraphs.

44. On information and belief, Emcure has infringed at least one claim of the '692 Patent, pursuant to 35 U.S.C. § 271(e)(2)(A), by submitting the Emcure ANDA, by which Emcure seeks approval from the FDA to engage in the commercial manufacture, use, offer to sell, sale within the United States, or importation into the United States of the Emcure ANDA Products prior to the expiration of the '692 Patent.

45. Moreover, if Emcure manufactures, uses, sells, offers for sale, or imports into the United States, the Emcure ANDA Products, or induces or contributes to any such conduct, prior to the expiration of the '692 Patent, including any applicable exclusivities or extensions, Emcure would further infringe (either literally or under the doctrine of equivalents) at least one claim of the '692 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

46. Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4), including an order of this Court that the effective date of the approval of the Emcure ANDA be a date that is

not earlier than the expiration of the term of the '692 Patent, including any extension(s) granted by the PTO pursuant to 35 U.S.C. §§ 154 or 156, or any late expiration of exclusivity for the '692 Patent to which Plaintiffs are or become entitled.

47. Plaintiffs will be substantially and irreparably harmed if Emcure is not enjoined from infringing the '692 Patent.

48. Plaintiffs have no adequate remedy at law.

49. This case is exceptional, and Plaintiffs are entitled to an award of attorneys' fees under 35 U.S.C. § 285.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs seek relief as follows:

1. A judgment that Emcure has infringed one or more valid claims of the '340, '987 and '692 Patents by submitting or causing to be submitted the Emcure ANDA to the FDA to obtain approval for the commercial manufacture, use, import, offer for sale, and/or sale in the United States of the Emcure ANDA Products before the expiration of the Patents-in-Suit;

2. A judgment pursuant to 35 U.S.C. § 271(e)(4)(B) for a preliminary and permanent injunction enjoining Emcure, its officers, agents, servants, employees, and those persons acting in active concert or participation with all or any of them from manufacturing, using, offering to sell, or selling the Emcure ANDA Products within the United States, or importing the Emcure ANDA Products into the United States, prior to the expiration of the Patents-in-Suit;

3. A judgment ordering that pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of the Emcure ANDA under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)) shall not be earlier than the latest of the expiration dates of the '962, '340, '987 and/or '692 Patents, including any extensions;

4. A judgment declaring and enjoining Emcure, its officers, agents, servants, employees, and those persons acting in active concert or participation with all or any of them from manufacturing, using, offering to sell, or selling the Emcure ANDA Products and any other product that infringes or induces or contributes to the infringement of one or more claims of the Patents-in-Suit prior to their expiration, including any exclusivities or extensions to which Plaintiffs are or become entitled;

5. That Plaintiffs be awarded damages for their costs, disbursements, expert witness fees, and attorneys' fees and costs incurred in prosecuting this action, for an exceptional case pursuant to 35 U.S.C. § 285 and as otherwise provided by law; and

6. Such other and further relief as the Court deems just and appropriate.

Dated: June 28, 2019  
Newark, New Jersey

Respectfully submitted,

s/ William P. Deni, Jr.  
William P. Deni, Jr.  
Charles H. Chevalier  
J. Brugh Lower  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545  
wdeni@gibbonslaw.com  
cchevalier@gibbonslaw.com  
jlower@gibbonslaw.com

*Attorneys for Plaintiffs*

OF COUNSEL:

Thomas P. Steindler (*pro hac vice* to be submitted)  
**MCDERMOTT WILL & EMERY LLP**  
500 North Capitol Street N.W.  
Washington, D.C. 20001  
(202) 756-8000

Sami Sedghani (*pro hac vice* to be submitted)  
**McDERMOTT WILL & EMERY LLP**  
415 Mission Street, Suite 5600  
San Francisco, CA 94105-2533  
(628) 218-3908

**CERTIFICATION OF NON-ARBITRABILITY**  
**PURSUANT TO LOCAL CIVIL RULE 201.1(d)**

Pursuant to Local Civil Rule 201.1(d), the undersigned counsel hereby certifies that this action seeks declaratory and injunctive relief and, therefore, is not subject to mandatory arbitration.

I certify under penalty of perjury that the foregoing is true and correct.

Dated: June 28, 2019  
Newark, New Jersey

s/ William P. Deni, Jr.  
William P. Deni, Jr.  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545  
wdeni@gibbonslaw.com

*Attorneys for Plaintiffs*